HER-2 positive
Showing 1 - 25 of >10,000
HER2-positive Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Miami (Discontinuation of Anti-HER-2 Maintenance
Recruiting
- HER2-positive Metastatic Breast Cancer
- Stage IV Breast Cancer
- Discontinuation of Anti-HER-2 Maintenance Treatment
-
Miami, FloridaUniversity of Miami
Jul 17, 2023
HER2-positive Breast Cancer Trial in Guanzhou (Eribulin mesylate injection?Pertuzumab?Trastuzumab)
Recruiting
- HER2-positive Breast Cancer
- Eribulin mesylate injection、Pertuzumab、Trastuzumab
-
Guanzhou, Guangdong, ChinaLI YuDong
Jul 13, 2023
HER2-positive Locally Advanced Resectable Gastric Cancer Trial (KN026, KN046, XELOX)
Not yet recruiting
- HER2-positive Locally Advanced Resectable Gastric Cancer
- KN026
- +2 more
- (no location specified)
Sep 3, 2023
HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer Trial in Beijing (KN026, KN046, XELOX)
Not yet recruiting
- HER2-positive Colorectal Cancer
- HER2-positive Biliary Tract Cancer
- KN026
- +2 more
-
Beijing, State*, ChinaPeking University cancer hospital & institution
Aug 2, 2023
HER2-positive Gastric Cancer, Immunotherapy Trial in Shanghai (Disitamab Vedotin combined with fruquintinib and Tislelizumab)
Recruiting
- HER2-positive Gastric Cancer
- Immunotherapy
- Disitamab Vedotin combined with fruquintinib and Tislelizumab
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 8, 2023
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/
Not yet recruiting
- HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- SHR-A1811
- Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
- (no location specified)
Nov 6, 2023
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2
Recruiting
- HER2-positive Breast Cancer
- Early-stage Breast Cancer
- pyrotinib combined with Capecitabine
- treatment of physician's choice
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Sep 6, 2023
HER2-positive Breast Cancer Trial in Shanghai (68Ga/131I-SGMIB-5F7)
Not yet recruiting
- HER2-positive Breast Cancer
- 68Ga/131I-SGMIB-5F7
-
Shanghai, ChinaHuashan Hospital
Aug 1, 2023
HER2-positive Advanced Breast Cancer Trial (DP303c, Trastuzumab, Vinorelbine Tartrate)
Not yet recruiting
- HER2-positive Advanced Breast Cancer
- DP303c
- +3 more
- (no location specified)
Jun 4, 2023
HER-2 Positive Advanced Solid Tumors Trial (D3L-001)
Not yet recruiting
- HER-2 Positive Advanced Solid Tumors
- D3L-001
- (no location specified)
Jul 20, 2023
HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma Trial (Trastuzumab deruxtecan)
Not yet recruiting
- HER2-positive Advanced Gastric Cancer
- HER2-positive Gastroesophageal Junction Adenocarcinoma
- Trastuzumab deruxtecan
- (no location specified)
Aug 11, 2023
HER2-Positive Cancer Trial in Wuhan
Active, not recruiting
- HER2-Positive Cancer
-
Wuhan, Hubei, ChinaTongjiHospital
Sep 7, 2022
Breast Tumor Female Trial in Beijing (CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou))
Recruiting
- Breast Neoplasm Female
- CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)
-
Beijing, Beijing, China
- +1 more
Jul 31, 2023
HER2-positive Advanced Solid Tumors Trial in Shanghai (DP303c)
Recruiting
- HER2-positive Advanced Solid Tumors
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 10, 2023
Breast Cancer Female Trial (Pyrotinib and Trastuzumab)
Not yet recruiting
- Breast Cancer Female
- Pyrotinib and Trastuzumab
- (no location specified)
Sep 11, 2023
HER2 Positive Advanced Solid Tumors Trial (HypoSti.CAR-HER2 T cells, Albumin-bound paclitaxel, Cyclophosphamide)
Not yet recruiting
- HER2 Positive Advanced Solid Tumors
- HypoSti.CAR-HER2 T cells
- +2 more
- (no location specified)
Jan 12, 2023
Sentinel Lymph Node Biopsy in Initially Lymph Node-positive,
Completed
- Breast Cancer
- Sentinel Lymph Node
- Test cohort
-
Fuzhou, Fujian, ChinaChuan Wang
Nov 25, 2023
Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab Trial in Guangzhou (Trastuzumab and
Recruiting
- Early-stage Breast Cancer
- +4 more
- Trastuzumab and nelatinib
- Trastuzumab and Parstuzumab
-
Guangzhou, ChinaSun Yat-sen University Sun Yat-sen Memorial Hospital
Mar 12, 2023
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy Trial (SHR-A1811,
Not yet recruiting
- HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
- SHR-A1811
- Trastuzumab Emtansine
- (no location specified)
Nov 7, 2023
Early On-treatment Transcriptional Profiling as Predictor of
Recruiting
- HER2-positive Breast Cancer
- +2 more
- Trastuzumab (neoadjuvant)
- +2 more
-
Hospitalet de Llobregat, Barcelona, SpainInstitut Català d'Oncologia l'Hospitalet
Jun 12, 2023
HER2 Positive Early Breast Cancer Trial in Shanghai (Docetaxel, carboplatin, Trastuzumab)
Recruiting
- HER2 Positive Early Breast Cancer
- Docetaxel
- +5 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center Shanghai, China, 200032
Jun 6, 2023
HER2-positive Breast Cancer Trial in Nanjing (HS022, Trastuzumab, Vinorelbine Bitartrate)
Completed
- HER2-positive Breast Cancer
- HS022
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Province People's Hospital (First Affiliated Hospital of
Oct 25, 2023
Brain Metastases, HER2-positive Breast Cancer Trial (Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine)
Not yet recruiting
- Brain Metastases
- HER2-positive Breast Cancer
- Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine
- (no location specified)
Jan 10, 2023